PWM
LXRX icon

Perigon Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Perigon Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,489
Closed -$30K – 462
2018
Q1 		$30K Hold
3,489
– – 0.01% 379
2017
Q4 		$34K Hold
3,489
– – 0.01% 338
2017
Q3 		$43K Buy
+3,489
New +$51.5K 0.01% 359

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
SGA
Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Perigon Wealth Management's LXRX Position: Q2 2018 in Review

Perigon Wealth Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2018, closing a stake of 3,489 shares — an estimated $30K sold.

Perigon Wealth Management first reported a position in LXRX in Q3 2017 and held it in 3 quarters. The position peaked at $43K in Q3 2017. 121 funds tracked by Wall St. Rank hold LXRX as of Q2 2018.

  • Perigon Wealth Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Perigon Wealth Management sold 3,489 Lexicon Pharmaceuticals shares in Q2 2018, an estimated $30K.
  • Perigon Wealth Management first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Perigon Wealth Management's Lexicon Pharmaceuticals position peaked at $43K in Q3 2017.
  • 121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2018.

Based on Perigon Wealth Management's 13F filing for Q2 2018, filed 7 Aug 2018.